{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:06:35Z","timestamp":1793963195140,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10072-023-06680-5","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T09:03:10Z","timestamp":1677229390000},"page":"1931-1947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Neurofibromatosis type 1 system-based manifestations and treatments: a review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2757-113X","authenticated-orcid":false,"given":"Mustafa","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-6917","authenticated-orcid":false,"given":"AlFadel","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-8135","authenticated-orcid":false,"given":"Sarah","family":"Beaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-4362","authenticated-orcid":false,"given":"Charbel","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-8365","authenticated-orcid":false,"given":"Sary","family":"Faraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-0875","authenticated-orcid":false,"given":"Youssef","family":"El Joueid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Kotob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Saoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-0678","authenticated-orcid":false,"given":"Nancy","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"issue":"3","key":"6680_CR1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","volume":"135","author":"E Uusitalo","year":"2015","unstructured":"Uusitalo E, Lepp\u00e4virta J, Koffert A et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 135(3):904\u2013906. https:\/\/doi.org\/10.1038\/jid.2014.465","journal-title":"J Invest Dermatol"},{"issue":"10","key":"6680_CR2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00381-020-04731-2","volume":"36","author":"AM Gross","year":"2020","unstructured":"Gross AM, Dombi E, Widemann BC (2020) Current status of MEK inhibitors in the treatment of plexiform neurofibromas. Child Nervous Syst 36(10):2443\u20132452. https:\/\/doi.org\/10.1007\/s00381-020-04731-2 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32607696)","journal-title":"Child Nervous Syst"},{"issue":"7-S","key":"6680_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.23750\/abm.v91i7-S.9961","volume":"91","author":"T Foiadelli","year":"2020","unstructured":"Foiadelli T, Naso M, Licari A et al (2020) Advanced pharmacological therapies for neurofibromatosis type 1-related tumors. Acta Bio-Medica Atenei Parmensis 91(7-S):101\u2013114. https:\/\/doi.org\/10.23750\/abm.v91i7-S.9961 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32608378)","journal-title":"Acta Bio-Medica Atenei Parmensis"},{"issue":"15","key":"6680_CR4","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.3390\/cancers13153880","volume":"13","author":"Omar Rabab\u2019h","year":"2021","unstructured":"Rabab\u2019h Omar, Gharaibeh Abeer, Al-Ramadan Ali, Ismail Manar, Shah Jawad (2021) Pharmacological approaches in neurofibromatosis type 1-associated nervous system tumors. Cancers 13(15):3880. https:\/\/doi.org\/10.3390\/cancers13153880 (https:\/\/search.proquest.com\/docview\/2558730913)","journal-title":"Cancers"},{"issue":"5","key":"6680_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/14728222.2018.1465931","volume":"22","author":"JA Walker","year":"2018","unstructured":"Walker JA, Upadhyaya M (2018) Emerging therapeutic targets for neurofibromatosis type 1. Expert Opin Ther Targets 22(5):419\u2013437. https:\/\/doi.org\/10.1080\/14728222.2018.1465931 (https:\/\/pubmed.ncbi.nlm.nih.gov\/29667529)","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"6680_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/gim.2018.28","volume":"20","author":"DR Stewart","year":"2018","unstructured":"Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K (2018) Care of adults with neurofibromatosis type 1: a clinical practice resource of the american college of medical genetics and genomics (ACMG). Genet Med 20(7):671\u2013682. https:\/\/doi.org\/10.1038\/gim.2018.28","journal-title":"Genet Med"},{"issue":"8","key":"6680_CR7","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P et al (2021) Revised diagnostic criteria for neurofibromatosis type 1 and legius syndrome: an international consensus recommendation. Genet Med 23(8):1506\u20131513. https:\/\/doi.org\/10.1038\/s41436-021-01170-5","journal-title":"Genet Med"},{"issue":"1","key":"6680_CR8","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1038\/hgv.2015.51","volume":"2","author":"M Bianchi","year":"2015","unstructured":"Bianchi M, Saletti V, Micheli R et al (2015) Legius syndrome: two novel mutations in the SPRED1 gene. Human Genome Variation 2(1):15051. https:\/\/doi.org\/10.1038\/hgv.2015.51","journal-title":"Human Genome Variation"},{"key":"6680_CR9","doi-asserted-by":"publisher","unstructured":"Sabatini C, Milani D, Menni F, Tadini G, Esposito S (2015) Treatment of neurofibromatosis type 1. Curr Treat Options Neurol 17(6). https:\/\/doi.org\/10.1007\/s11940-015-0355-4","DOI":"10.1007\/s11940-015-0355-4"},{"key":"6680_CR10","doi-asserted-by":"publisher","unstructured":"Chamseddin BH, Hernandez L, Solorzano D, Vega J, Le LQ (2019) Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1. JCI Insight 4(11). https:\/\/doi.org\/10.1172\/jci.insight.128881","DOI":"10.1172\/jci.insight.128881"},{"issue":"3","key":"6680_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1620\/tjem.217.193","volume":"217","author":"M Yamamoto","year":"2009","unstructured":"Yamamoto M, Yamauchi T, Okano K, Takahashi M, Watabe S, Yamamoto Y (2009) Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Tohoku J Exp Med 217(3):193\u2013201. https:\/\/doi.org\/10.1620\/tjem.217.193 (https:\/\/www.jstage.jst.go.jp\/article\/tjem\/217\/3\/217_3_193\/_article\/-char\/en)","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"6680_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40268-018-0248-6","volume":"18","author":"JM Slopis","year":"2018","unstructured":"Slopis JM, Arevalo O, Bell CS et al (2018) Treatment of disfiguring cutaneous lesions in neurofibromatosis-1 with everolimus: a phase II, open-label, single-arm trial. Drugs R D 18(4):295. https:\/\/doi.org\/10.1007\/s40268-018-0248-6","journal-title":"Drugs R D"},{"issue":"Supplement_1","key":"6680_CR13","doi-asserted-by":"publisher","first-page":"i107","DOI":"10.1093\/noajnl\/vdz034","volume":"2","author":"BH Chamseddin","year":"2020","unstructured":"Chamseddin BH, Le LQ (2020) Management of cutaneous neurofibroma: current therapy and future directions. Neuro-Oncology Adv 2(Supplement_1):i107\u2013i116. https:\/\/doi.org\/10.1093\/noajnl\/vdz034 (https:\/\/search.proquest.com\/docview\/2422004152)","journal-title":"Neuro-Oncology Adv"},{"key":"6680_CR14","doi-asserted-by":"publisher","unstructured":"Tsuji G, Takai-Yumine A, Kato T, Furue M (2021) Metalloproteinase 1 downregulation in neurofibromatosis 1: therapeutic potential of antimalarial hydroxychloroquine and chloroquine. Cell Death Dis 12(6). https:\/\/doi.org\/10.1038\/s41419-021-03802-9","DOI":"10.1038\/s41419-021-03802-9"},{"issue":"6","key":"6680_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ejim.2014.04.004","volume":"25","author":"G Tadini","year":"2014","unstructured":"Tadini G, Milani D, Menni F, Pezzani L, Sabatini C, Esposito S (2014) Is it time to change the neurofibromatosis 1 diagnostic criteria? Eur J Intern Med 25(6):506\u2013510. https:\/\/doi.org\/10.1016\/j.ejim.2014.04.004 (https:\/\/www.clinicalkey.es\/playcontent\/1-s2.0-S0953620514001083)","journal-title":"Eur J Intern Med"},{"issue":"1","key":"6680_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/iwj.12599","volume":"14","author":"B Chen","year":"2017","unstructured":"Chen B, Xu M, Song H, Gao Q (2017) Clinical experience of surgically treating giant neurofibromatosis-1. Int Wound J 14(1):271\u2013276. https:\/\/doi.org\/10.1111\/iwj.12599 (https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/iwj.12599)","journal-title":"Int Wound J"},{"issue":"10","key":"6680_CR17","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","volume":"22","author":"NJ Ullrich","year":"2020","unstructured":"Ullrich NJ, Prabhu SP, Reddy AT et al (2020) A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1\u2013associated pediatric low-grade glioma: a neurofibromatosis clinical trials consortium study. Neuro-oncology (Charlottesville, Va.) 22(10):1527\u20131535. https:\/\/doi.org\/10.1093\/neuonc\/noaa071 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32236425)","journal-title":"Neuro-oncology (Charlottesville, Va.)"},{"issue":"1","key":"6680_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2008.12.051","volume":"61","author":"KP Boyd","year":"2009","unstructured":"Boyd KP, Korf BR, Theos A (2009) Neurofibromatosis type 1. J Am Acad Dermatol 61(1):1\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2008.12.051","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"6680_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/pch\/12.9.771","volume":"12","author":"JA Janicki","year":"2007","unstructured":"Janicki JA, Alman B (2007) Scoliosis: review of diagnosis and treatment. Paediatr Child Health 12(9):771\u2013776. https:\/\/doi.org\/10.1093\/pch\/12.9.771","journal-title":"Paediatr Child Health"},{"issue":"9","key":"6680_CR20","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1007\/s00586-018-5679-9","volume":"27","author":"H Tan","year":"2018","unstructured":"Tan H, Shen J, Feng F et al (2018) Clinical manifestations and radiological characteristics in patients with idiopathic syringomyelia and scoliosis. Eur Spine J 27(9):2148\u20132155. https:\/\/doi.org\/10.1007\/s00586-018-5679-9","journal-title":"Eur Spine J"},{"issue":"2","key":"6680_CR21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.21873\/anticanres.13181","volume":"39","author":"J Mehlan","year":"2019","unstructured":"Mehlan J, Sch\u00fcttauf F, Salamon JM, Kordes U, Friedrich RE, Mautner V (2019) Manifestations and treatment of adult-onset symptomatic optic pathway glioma in neurofibromatosis type 1. Anticancer Res 39(2):827\u2013831. https:\/\/doi.org\/10.21873\/anticanres.13181 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30711963)","journal-title":"Anticancer Res"},{"issue":"1","key":"6680_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/0883073817739196","volume":"33","author":"RJ Packer","year":"2018","unstructured":"Packer RJ, Fisher MJ, Cutter G, Cole-Plourde K, Korf BR (2018) Neurofibromatosis clinical trial consortium. J Child Neurol 33(1):82\u201391. https:\/\/doi.org\/10.1177\/0883073817739196 (https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/0883073817739196)","journal-title":"J Child Neurol"},{"key":"6680_CR23","doi-asserted-by":"publisher","unstructured":"Ullrich NJ, Prabhu SP, Packer RJ, et al (2020) Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1\u2010associated optic pathway gliomas in children. Pediatr Blood Cancer 68(4). https:\/\/doi.org\/10.1002\/pbc.28833","DOI":"10.1002\/pbc.28833"},{"issue":"2","key":"6680_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/now158","volume":"19","author":"RI Jakacki","year":"2017","unstructured":"Jakacki RI, Dombi E, Steinberg SM et al (2017) Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro-oncology (Charlottesville, Va.) 19(2):289\u2013297. https:\/\/doi.org\/10.1093\/neuonc\/now158 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27510726)","journal-title":"Neuro-oncology (Charlottesville, Va.)"},{"issue":"4","key":"6680_CR25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/neuonc\/nou235","volume":"17","author":"B Weiss","year":"2015","unstructured":"Weiss B, Widemann BC, Wolters P et al (2015) Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis clinical trials consortium phase II study. Neuro-oncology (Charlottesville, Va.) 17(4):596\u2013603. https:\/\/doi.org\/10.1093\/neuonc\/nou235 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25314964)","journal-title":"Neuro-oncology (Charlottesville, Va.)"},{"issue":"26","key":"6680_CR26","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ et al (2016) Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas. N Engl J Med 375(26):2550\u20132560. https:\/\/doi.org\/10.1056\/NEJMoa1605943","journal-title":"N Engl J Med"},{"issue":"4","key":"6680_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/23808993.2021.1917989","volume":"6","author":"LK Metrock","year":"2021","unstructured":"Metrock LK, Lobbous M, Korf B (2021) An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromas. Expert Rev Precision Med Drug Dev 6(4):239\u2013246. https:\/\/doi.org\/10.1080\/23808993.2021.1917989 (http:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/23808993.2021.1917989)","journal-title":"Expert Rev Precision Med Drug Dev"},{"issue":"15","key":"6680_CR28","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E et al (2020) Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 382(15):1430\u20131442. https:\/\/doi.org\/10.1056\/NEJMoa1912735","journal-title":"N Engl J Med"},{"key":"6680_CR29","doi-asserted-by":"publisher","unstructured":"Sweeney EE, Burga RA, Li C, Zhu Y, Fernandes R (2016) Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Sci Rep 6(1). https:\/\/doi.org\/10.1038\/srep37035","DOI":"10.1038\/srep37035"},{"issue":"8","key":"6680_CR30","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/bjc.2015.345","volume":"113","author":"YC Shen","year":"2015","unstructured":"Shen YC, Upadhyayula R, Cevallos S, Messick RJ, Hsia T, Leese MP, Jewett DM, Ferrer-Torres D, Roth TM, Dohle W, Potter BV, Barald KF (2015) Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol. Br J Cancer 113(8):1158\u201367. https:\/\/doi.org\/10.1038\/bjc.2015.345","journal-title":"Br J Cancer"},{"issue":"2","key":"6680_CR31","doi-asserted-by":"publisher","first-page":"909","DOI":"10.21873\/anticanres.13193","volume":"39","author":"V Vitolo","year":"2019","unstructured":"Vitolo V, Fiore MR, Barcellini A et al (2019) Carbon ion radiotherapy in the management of the tumors of the peripheral nervous system. Anticancer Res 39(2):909. https:\/\/doi.org\/10.21873\/anticanres.13193","journal-title":"Anticancer Res"},{"key":"6680_CR32","doi-asserted-by":"publisher","first-page":"8685638","DOI":"10.1155\/2017\/8685638","volume":"2017","author":"CS Higham","year":"2017","unstructured":"Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC (2017) SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors. Sarcoma 2017:8685638. https:\/\/doi.org\/10.1155\/2017\/8685638","journal-title":"Sarcoma"},{"issue":"3","key":"6680_CR33","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jid.2018.09.016","volume":"139","author":"O Zehou","year":"2019","unstructured":"Zehou O, Ferkal S, Brugieres P, Barbarot S, Bastuji-Garin S, Combemale P, Valeyrie-Allanore L, Sbidian E, Wolkenstein P (2019) Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: results from a phase 2a trial. J Invest Dermatol 139(3):718\u2013720. https:\/\/doi.org\/10.1016\/j.jid.2018.09.016","journal-title":"J Invest Dermatol"},{"issue":"7","key":"6680_CR34","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/ped.14183","volume":"62","author":"ME Mateos","year":"2020","unstructured":"Mateos ME, L\u00f3pez-laso E, Vicente J, Ortega R, V\u00e1zquez F, P\u00e9rez-navero JL (2020) Response to everolimus of a progressive plexiform neurofibroma in neurofibromatosis type 1. Pediatr Int 62(7):857. https:\/\/doi.org\/10.1111\/ped.14183","journal-title":"Pediatr Int"},{"key":"6680_CR35","doi-asserted-by":"publisher","unstructured":"Zehou O, Ferkal S, Brugieres P, Barbarot S, Bastuji-Garin S, Combemale P, Valeyrie-Allanore L, Sbidian E, Wolkenstein P (2019) Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: results from a Phase 2a trial. J Invest dermatol, 139(3):718\u2013720. https:\/\/doi.org\/10.1016\/j.jid.2018.09.016","DOI":"10.1016\/j.jid.2018.09.016"},{"key":"6680_CR36","doi-asserted-by":"publisher","unstructured":"Mateos ME, L\u00f3pez-Laso E, Vicente J, Ortega R, V\u00e1zquez F, P\u00e9rez-Navero JL (2020) Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1. Pediatr Int: Official J Japan Pediatr Soc 62(7):857\u2013859. https:\/\/doi.org\/10.1111\/ped.14183","DOI":"10.1111\/ped.14183"},{"issue":"2","key":"6680_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11060-014-1652-6","volume":"121","author":"A Cappellano","year":"2015","unstructured":"Cappellano A, Petrilli A, da Silva N et al (2015) Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol 121(2):405\u2013412. https:\/\/doi.org\/10.1007\/s11060-014-1652-6 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25366366)","journal-title":"J Neurooncol"},{"issue":"10","key":"6680_CR38","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","volume":"22","author":"NJ Ullrich","year":"2020","unstructured":"Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, Robison NJ, Gutmann DH, Viskochil DH, Allen JC, Korf B, Cantor A, Cutter G, Thomas C, Perentesis JP, Mizuno T, Vinks AA, Manley PE, Chi SN, Kieran MW (2020) A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol 22(10):1527\u20131535. https:\/\/doi.org\/10.1093\/neuonc\/noaa071","journal-title":"Neuro Oncol"},{"issue":"7","key":"6680_CR39","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20(7):1011\u20131022. https:\/\/doi.org\/10.1016\/S1470-2045(19)30277-3","journal-title":"Lancet Oncol"},{"issue":"1","key":"6680_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/cam4.1799","volume":"8","author":"N Zhukova","year":"2018","unstructured":"Zhukova N, Rajagopal RR, Lam A et al (2018) Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma. Cancer Med 8(1):40. https:\/\/doi.org\/10.1002\/cam4.1799","journal-title":"Cancer Med"},{"key":"6680_CR41","doi-asserted-by":"publisher","first-page":"vi145","DOI":"10.1093\/neuonc\/now212.606","volume":"18","author":"MI Vanan","year":"2016","unstructured":"Vanan MI, Kazina C, Clark I, Krawitz S, Bunge M (2016) Cochrane Central Register of Controlled Trials, Marked recovery of vision in a child with optic pathway glioma treated upfront with bevacizumab and vinblastine. Neuro-oncology 18:vi145","journal-title":"Neuro-oncology"},{"key":"6680_CR42","unstructured":"Cochrane Central Register of Controlled Trials (2019) Selumetinib versus carboplatin\/vincristine in treating patients with newly diagnosed or previously untreated NF1-associated low-grade glioma, NCT03871257. https:\/\/clinicaltrials.gov\/show\/NCT03871257"},{"key":"6680_CR43","doi-asserted-by":"publisher","first-page":"vi145","DOI":"10.1093\/neuonc\/now212.604","volume":"18","author":"C Clinic","year":"2016","unstructured":"Clinic C, Cleveland Mohler A et al (2016) PALL-06 Improving patient outcomes through a multidisciplinary neuro-oncology rehabilitation clinic. Neuro-Oncology 18:vi145","journal-title":"Neuro-Oncology"},{"issue":"3","key":"6680_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1684\/ejd.2018.3259","volume":"28","author":"M Kinoshita","year":"2018","unstructured":"Kinoshita M, Ogawa Y, Takeichi T et al (2018) Impetigo herpetiformis with IL-36RN mutation successfully treated with secukinumab. Eur J Dermatol 28(3):381\u2013382. https:\/\/doi.org\/10.1684\/ejd.2018.3259 (https:\/\/link.springer.com\/article\/10.1684\/ejd.2018.3259)","journal-title":"Eur J Dermatol"},{"issue":"10","key":"6680_CR45","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s00381-020-04704-5","volume":"36","author":"RJ Packer","year":"2020","unstructured":"Packer RJ, Vezina G (2020) New treatment modalities in NF-related neuroglial tumors. Childs Nerv Syst 36(10):2377\u20132384. https:\/\/doi.org\/10.1007\/s00381-020-04704-5 (https:\/\/link.springer.com\/article\/10.1007\/s00381-020-04704-5)","journal-title":"Childs Nerv Syst"},{"issue":"2","key":"6680_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1179\/2295333714Y.0000000094","volume":"70","author":"IC Benlidayi","year":"2015","unstructured":"Benlidayi IC, Ortac EA, Kozanoglu E (2015) Risedronate therapy for neurofibromatosis type 1-related low bone mass: a stitch in time saves nine. Acta Clin Belgica 70(2):130\u2013132. https:\/\/doi.org\/10.1179\/2295333714Y.0000000094 (http:\/\/www.tandfonline.com\/doi\/abs\/10.1179\/2295333714Y.0000000094)","journal-title":"Acta Clin Belgica"},{"issue":"6","key":"6680_CR47","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ajmg.a.37623","volume":"170A","author":"S Martin","year":"2016","unstructured":"Martin S, Wolters PL, Toledo-Tamula MA et al (2016) Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: a pilot study of feasibility and preliminary efficacy. Am J Med Gen Part A 170A(6):1462\u20131470. https:\/\/doi.org\/10.1002\/ajmg.a.37623 (https:\/\/api.istex.fr\/ark:\/67375\/WNG-27M3JL12-J\/fulltext.pdf)","journal-title":"Am J Med Gen Part A"},{"key":"6680_CR48","doi-asserted-by":"publisher","unstructured":"Pride NA, Barton B, Hutchins P, et al (2018) Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial. BMJ Open 8(8). https:\/\/doi.org\/10.1136\/bmjopen-2018-021800.","DOI":"10.1136\/bmjopen-2018-021800"},{"issue":"1","key":"6680_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","volume":"27","author":"MJ Fisher","year":"2021","unstructured":"Fisher MJ, Shih C, Rhodes SD et al (2021) Cabozantinib for neurofibromatosis type 1\u2013related plexiform neurofibromas: a phase 2 trial. Nat Med 27(1):165. https:\/\/doi.org\/10.1038\/s41591-020-01193-6","journal-title":"Nat Med"},{"issue":"3","key":"6680_CR50","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1684\/ejd.2018.3265","volume":"28","author":"T Ogawa","year":"2018","unstructured":"Ogawa T, Ishitsuka Y, Inoue S, Fujisawa Y, Fujimoto M (2018) Neurofibromatosis type 1-associated serious haemorrhagic events successfully treated with steroid pulse therapy (Letter). Eur J Dermatol 28(3):382\u2013384","journal-title":"Eur J Dermatol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06680-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T03:52:35Z","timestamp":1683863555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06680-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6680"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06680-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"26 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}